What is Apicore US?
Apicore US is a privately held developer and manufacturer of specialty Active Pharmaceutical Ingredients (APIs) and pharmaceuticals, headquartered in New Jersey. The company boasts a portfolio of over 15 Abbreviated New Drug Applications (ANDAs), with one partnered with Medicure. Apicore's manufacturing capabilities are robust, producing over 100 different APIs, including 35 for which Drug Master Files have been submitted to the FDA and 16 approved for commercial sale in the U.S. The company specializes in the synthesis of complex, high-value, and niche APIs for both U.S. and international generic and branded pharmaceutical firms. Apicore operates two FDA-approved facilities: a Somerset, New Jersey site capable of producing volumes from grams to 200 kg, and a Vadodara, Gujarat facility in India with an annual capacity of up to 60 metric tons. Both sites are equipped with advanced analytical and research infrastructure, positioning Apicore as a key player in the API manufacturing landscape.
How much funding has Apicore US raised?
Apicore US has raised a total of $16.7M across 3 funding rounds:
Unspecified
$9.2M
Unspecified
$6.8M
Private Equity
$720K
Unspecified (2014): $9.2M with participation from Undisclosed
Unspecified (2014): $6.8M led by Undisclosed
Private Equity (2016): $720K, investors not publicly disclosed
What's next for Apicore US?
The recent major strategic investment signifies a pivotal moment for Apicore US, likely enabling the company to accelerate its expansion, enhance its research and development initiatives, and potentially broaden its manufacturing capacity. This capital infusion is expected to fuel further growth in its specialty API segment and support the commercialization of its existing ANDAs. The company's focus on difficult-to-synthesize APIs and its dual-facility infrastructure suggest a strategic push towards capturing a larger market share in high-value pharmaceutical ingredients, positioning Apicore for sustained development and market leadership.
See full Apicore US company page
